Eli Lilly and Company announced positive topline results of the SURMOUNT-OSA phase III clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints
Gilead Sciences announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines...
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for the once-daily single tablet regimen Genvoya (elvitegravir...